Please login to the form below

Not currently logged in
Email:
Password:
PMLiVE Top Pharma List

19

Revenue 2017

Celgene

The Top Pharma List rankings are compiled from GlobalData's pharmaceutical revenue figures, which are based on prescription medicine sales, including generics drugs. They have been compiled below into an infographic of Celgene's 2013 oncology sales performance.

Celgene

Armed with new data, BMS plans filings for Celgene CAR-T liso-cel

Armed with new data, BMS plans filings for Celgene CAR-T liso-cel Achieved a 53% complete response rate in study participants. Shortly after closing its takeover of Celgene, Bristol-Myers Squibb has reported a positive trial for liso-cel, one of the  ... Before being taken over, Celgene had suggested that liso-cel

BMS, Acceleron Pharma’s Reblozyl to be reviewed by FDA expert panel

BMS, Acceleron Pharma’s Reblozyl to be reviewed by FDA expert panel The drug was originally developed by Celgene, which was finally acquired by BMS  last month after the merger was initially announced in January. ... The approval of Reblozyl in beta thalassaemia and the potential approval in MDS will buoy the newly

Amgen raises forecasts after closing $13.4bn Otezla deal

Amgen raises forecasts after closing $13.4bn Otezla deal Amgen lost no time completing its acquisition of psoriasis blockbuster Otezla in the wake of the Bristol-Myers Squibb/Celgene merger, and promptly raised its 2019 sales forecasts. ... Some workers will be joining Amgen from Celgene as a result of the

New hires at Abbott, Kite and Arrakis Therapeutics

New hires at Abbott, Kite and Arrakis Therapeutics Previously, he spent many years at Celgene, where he was corporate vice president for clinical R7D and the therapeutic area head for Lymphoma and CLL. ... Most recently, Bosley served as the chief executive officer of Editas Medicine, and previously

J&J’s new Darzalex formulation OK’d for use in Europe

J&J’s new Darzalex formulation OK’d for use in Europe The  new approval means that Darzalex, in combination with Celgene’s Revlimid (lenalidomide) and dexamethasone, (DRd) can be administered for the treatment of newly diagnosed multiple myeloma patients who are ineligible

[ Previous 5 results ] 6 7 8 9 10 11 12 13 14 15 [ Next 5 results ]

Subscribe to our email news alerts

Featured jobs

PMHub

Add my company
IGNIFI

We’re IGNIFI. An independent creative agency, we help spark and sustain successful brands for some of the biggest names in...

Latest intelligence

KOL Ambassador Program & Podcast Creation: A Customer Story
...
Animation: Living With
The journey from the patient's perspective...
Danny Buckland July2022
Achieving communication excellence by targeting the right channel at the right time
By Danny Buckland...